Shares of Celgene Corporation (NASDAQ:CELG) ended Friday session in red amid volatile trading. The shares closed down -3.18 points or -2.95% at $104.47 with 4.34 million shares getting traded. Post opening the session at $106.80, the shares hit an intraday low of $104.42 and an intraday high of $106.97 and the price vacillated in this range throughout the day. The company has a market cap of $78.58 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
Celgene Corporation (CELG) announced that it plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company’s website at www.celgene.com.
Monday, September 12, 2016, Celgene will present at the Morgan Stanley Global Healthcare Unplugged Conference in New York City at 2:50 pm ET
Thursday, September 29, 2016, Celgene will webcast an R&D Deep Dive on Protein Homeostasis beginning at 1:30pm ET. The webcast is expected to conclude at 5pm ET.
Shares of St. Jude Medical, Inc. (NYSE:STJ) ended Friday session in red amid volatile trading. The shares closed down -1.35 points or -1.70% at $78.04 with 4,263,959 shares getting traded. Post opening the session at $78.94, the shares hit an intraday low of $78.04 and an intraday high of $79.01 and the price vacillated in this range throughout the day. The company has a market cap of $21.86 billion and the numbers of outstanding shares have been calculated to be 284.93 million shares.
St. Jude Medical, Inc. (STJ) on September 1, 2016 announced the start of the St. Jude Medical AMPLATZER™ Amulet™ IDE trial, which will evaluate the safety and effectiveness of the company’s AMPLATZER™ Amulet™ Left Atrial Appendage Occluder used to close the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF). The first implant of the study took place at North Mississippi Medical Center in Tupelo, Mississippi by Dr. Jim Stone.
In most people, the LAA — a small appendage connected to the left atrium — does not increase the risk of adverse health effects, but in some patients with atrial fibrillation, the LAA does not contract effectively and it can become a source of blood clots. These clots can then be released into the heart and enter the bloodstream, where they can travel to the brain and cause a stroke. Currently, patients with AF at risk of stroke are often prescribed blood-thinning medication, but this treatment approach comes with a lifetime of medical management and the risk of major bleeding. By closing the LAA with the AMPLATZER Amulet occluder, physicians can “seal off” the LAA and potentially reduce the risk of stroke.
The AMPLATZER Amulet occluder works by blocking the LAA at its opening, which minimizes the opportunity for blood clots to form in the LAA and migrate into the bloodstream. The AMPLATZER Amulet occluder, the second-generation St. Jude Medical LAA occlusion device, is built with a longer lobe and waist than the previous version and designed to allow for easier and more stable placement, which could result in shorter procedure times for patients. The AMPLATZER Amulet device is also offered in eight sizes to accommodate varying anatomies.
“There’s a real need within the United States medical community for a left atrial appendage occluder that addresses a wider range of complex patient anatomies,” said Dr. Dhanunjaya Lakkireddy, Professor of Medicine and the Director of the Center for Excellence in Atrial Fibrillation and Complex Arrhythmias at the University of Kansas. “The Amulet device has been used successfully in Europe, and I see this IDE trial as the right step toward providing patients with atrial fibrillation the optimal level of care to further reduce the risk of stroke.”